Greenland Mines (NASDAQ: GRML) has announced a series of corporate milestones that signal a decisive shift toward becoming a focused rare earths and critical minerals company. The company revealed plans to spin off its biotechnology division in the fourth quarter of 2026, a move that will allow it to concentrate resources on its mining operations, particularly the Sarfartoq neodymium-praseodymium (NdPr) rare earths project in southwest Greenland and the Skaergaard palladium-gold-platinum project in southeast Greenland.
The announcement comes as Greenland Mines achieves full compliance with Nasdaq listing requirements. Nasdaq has formally approved the company's application related to its March 2026 transaction, resolving prior deficiencies. This compliance milestone is crucial for maintaining investor confidence and ensuring the company's continued listing on the exchange.
On September 1, the company completed the acquisition of the Sarfartoq project following approval by the Government of Greenland. This acquisition is a cornerstone of Greenland Mines' strategy to build a multi-asset platform with exposure to rare earth magnet materials. An independent S-K 1300 Initial Assessment for the ST1 deposit at Sarfartoq has yielded impressive figures: a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. These numbers underscore the economic viability of the project.
The strategic importance of Sarfartoq extends beyond financial metrics. Planned annual NdPr oxide production from the ST1 deposit would equal approximately 34% of current NdPr oxide refining outside China, based on 2025 consumption levels, during each of the project's nine scheduled operating years. This positions Greenland Mines as a significant player in the global rare earths supply chain, particularly as Western nations seek to reduce dependence on Chinese rare earth processing.
The company is also reshaping its board to align with its new focus. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and Jason Hawkins, a capital markets veteran, is joining. Hawkins' experience is expected to support Greenland Mines as it advances the Sarfartoq and Skaergaard projects.
The biotech division, which includes Klotho's KLTO-202 primary indication for ALS, has been a part of Greenland Mines' portfolio. The spin-off will separate this business, allowing the mining division to operate with greater clarity and efficiency. The timing of the spin-off is set for Q4 2026, and details are expected to be announced in the coming months.
For industry observers, these developments signal a growing trend among companies to streamline operations and focus on critical minerals, which are essential for technologies like electric vehicles, wind turbines, and defense systems. The Sarfartoq project's high NPV and IRR, combined with the substantial production capacity relative to non-Chinese refining, highlight the project's potential to impact global supply chains. If successful, Greenland Mines could become a key supplier of NdPr oxide, a critical input for permanent magnets used in various high-tech applications.
The company's broader vision, the North Atlantic Critical Metals Corridor, aims to link Greenland's resources with allied downstream jurisdictions and industrial infrastructure. This strategic approach could enhance supply chain resilience for Western nations. As Greenland Mines transitions, investors and stakeholders will be watching closely to see how the spin-off and project advancements unfold. The company has emphasized that forward-looking statements involve risks, and actual results may differ materially. For more information, the full press release is available at IBN.fm/QN1U9.
